1Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer[J]. Oncologist, 2014,19 (10) : 1046-1049.
2Lu X, Liu DP, Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis [J]. Oncogene, 2013,32 (23) : 2900-2906.
3Yamashita K, Waraya M, Katoh H, et al. Epigenetic conversion on p53 pathway in human cancer: the clinical potential of p53 mutation status as a predictive biomarker for drug sensitivity by epigenetic treatment[J]. Cancer Res, 2013, 73(8 Supplement) : 4662-4671.
4Yang Z, Yuan XG, Chen J, et al. Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation[J]. Clin Res Hepatol Gastroenterol, 2013,37 (1) : 72-79.
5Busuttil RA, Zapparoli GV, Haupt S, et al. Role of p53 in the progression of gastric cancer[J]. Oneotarget, 2014,5 (23): 12016-12025.
6Saeki N, Ono H, Sakamoto H, et al. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study[J]. Cancer Sci,2013,104(1) :1-8.
7Kluth M, Harasimowicz S, Burkhardt L, et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer[J]. Int J Cancer, 2014, 135 (6):1369-1380.
8Leslie NR, den Hertog J. Mutant PTEN in cancer: worse than nothing[J]. Cell,2014,157(3) : 527-529.
9Dean SJ, Perks CM, Holly JM, et al. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer[J]. Am J Clin Pathol,2014,141(3) :323-333.
